Nature Reviews Clinical Oncology, Год журнала: 2020, Номер 17(10), С. 631 - 649
Опубликована: Май 28, 2020
Язык: Английский
CA A Cancer Journal for Clinicians, Год журнала: 2021, Номер 71(1), С. 7 - 33
Опубликована: Янв. 1, 2021
Each year, the American Cancer Society estimates numbers of new cancer cases and deaths in United States compiles most recent data on population-based occurrence. Incidence (through 2017) were collected by Surveillance, Epidemiology, End Results Program; National Program Registries; North Association Central Registries. Mortality 2018) Center for Health Statistics. In 2021, 1,898,160 608,570 are projected to occur States. After increasing 20th century, death rate has fallen continuously from its peak 1991 through 2018, a total decline 31%, because reductions smoking improvements early detection treatment. This translates 3.2 million fewer than would have occurred if rates had persisted. Long-term declines mortality 4 leading cancers halted prostate slowed breast colorectal cancers, but accelerated lung cancer, which accounted almost one-half 2014 2018. The pace annual doubled 3.1% during 2009 2013 5.5% 2018 men, 1.8% 4.4% women, 2.4% 5% overall. trend coincides with steady incidence (2.2%-2.3%) rapid gains survival specifically nonsmall cell (NSCLC). For example, NSCLC 2-year relative increased 34% persons diagnosed 2010 42% 2015 2016, including absolute increases 6% every stage diagnosis; small remained at 14% 15%. Improved treatment progress against drove record drop overall mortality, despite slowing momentum other common cancers.
Язык: Английский
Процитировано
14682
CA A Cancer Journal for Clinicians, Год журнала: 2022, Номер 72(1), С. 7 - 33
Опубликована: Янв. 1, 2022
Each year, the American Cancer Society estimates numbers of new cancer cases and deaths in United States compiles most recent data on population-based occurrence outcomes. Incidence (through 2018) were collected by Surveillance, Epidemiology, End Results program; National Program Registries; North Association Central Registries. Mortality 2019) Center for Health Statistics. In 2022, 1,918,030 609,360 are projected to occur States, including approximately 350 per day from lung cancer, leading cause death. during 2014 through 2018 continued a slow increase female breast (by 0.5% annually) remained stable prostate despite 4% 6% annual advanced disease since 2011. Consequently, proportion diagnosed at distant stage increased 3.9% 8.2% over past decade. contrast, incidence decline steeply while rates localized-stage suddenly 4.5% annually, contributing gains both diagnoses (from 17% 2004 28% 3-year relative survival 21% 31%). patterns reflect trends, with declines accelerating slowing stabilizing cancer. summary, progress has stagnated cancers but strengthened coinciding changes medical practice related screening and/or treatment. More targeted control interventions investment improved early detection treatment would facilitate reductions mortality.
Язык: Английский
Процитировано
14452
CA A Cancer Journal for Clinicians, Год журнала: 2023, Номер 73(1), С. 17 - 48
Опубликована: Янв. 1, 2023
Each year, the American Cancer Society estimates numbers of new cancer cases and deaths in United States compiles most recent data on population-based occurrence outcomes using incidence collected by central registries mortality National Center for Health Statistics. In 2023, 1,958,310 609,820 are projected to occur States. increased prostate 3% annually from 2014 through 2019 after two decades decline, translating an additional 99,000 cases; otherwise, however, trends were more favorable men compared women. For example, lung women decreased at one half pace (1.1% vs. 2.6% annually) 2015 2019, breast uterine corpus cancers continued increase, as did liver melanoma, both which stabilized aged 50 years older declined younger men. However, a 65% drop cervical during 2012 among their early 20s, first cohort receive human papillomavirus vaccine, foreshadows steep reductions burden papillomavirus-associated cancers, majority Despite pandemic, contrast with other leading causes death, death rate decline 2020 (by 1.5%), contributing 33% overall reduction since 1991 estimated 3.8 million averted. This progress increasingly reflects advances treatment, particularly evident rapid declines (approximately 2% 2016 2020) leukemia, kidney cancer, despite stable/increasing incidence, accelerated cancer. summary, although rates continue future may be attenuated rising breast, prostate, also happen have largest racial disparities mortality.
Язык: Английский
Процитировано
11813
CA A Cancer Journal for Clinicians, Год журнала: 2022, Номер 72(5), С. 409 - 436
Опубликована: Июнь 23, 2022
The number of cancer survivors continues to increase in the United States due growth and aging population as well advances early detection treatment. To assist public health community better serving these individuals, American Cancer Society National Institute collaborate triennially estimate prevalence using incidence survival data from Surveillance, Epidemiology, End Results registries, vital statistics Centers for Disease Control Prevention's Center Health Statistics, projections US Census Bureau. Current treatment patterns based on information Database are presented most prevalent types by race, cancer-related treatment-related side-effects also briefly described. More than 18 million Americans (8.3 males 9.7 females) with a history were alive January 1, 2022. 3 cancers prostate (3,523,230), melanoma skin (760,640), colon rectum (726,450) among breast (4,055,770), uterine corpus (891,560), thyroid (823,800) females. one-half (53%) diagnosed within past 10 years, two-thirds (67%) aged 65 years or older. One largest racial disparities is rectal cancer, which 41% Black patients stage I disease receive proctectomy proctocolectomy compared 66% White patients. Surgical receipt substantially lower non-small cell lung 49% stages I-II 16% III versus 55% 22% patients, respectively. These exacerbated fact that continue be less likely cancers, some female (53% vs 68%) endometrial (59% 73%). Although there growing tools can caregivers, clinicians navigating various phases survivorship, further evidence-based strategies equitable access available resources needed mitigate communities color optimize care people cancer. CA J Clin. 2022;72:409-436.
Язык: Английский
Процитировано
2929
CA A Cancer Journal for Clinicians, Год журнала: 2022, Номер 72(3), С. 202 - 229
Опубликована: Фев. 10, 2022
African American/Black individuals have a disproportionate cancer burden, including the highest mortality and lowest survival of any racial/ethnic group for most cancers. Every 3 years, American Cancer Society estimates number new cases deaths Black people in United States compiles recent data on incidence (herein through 2018), (through 2019), survival, screening, risk factors using population-based from National Institute Centers Disease Control Prevention. In 2022, there will be approximately 224,080 73,680 among States. During 5-year period, men had 6% higher rate but 19% than White overall, an 2-fold death myeloma, stomach cancer, prostate cancer. The overall disparity is narrowing between because steeper drop lung However, decline slowed 5% annually during 2010 2014 to 1.3% 2015 2019, likely reflecting annual increase advanced-stage diagnoses since 2012. women 8% lower 12% mortality; further, rates are endometrial 41% breast despite similar or rates. wide reflects both later stage diagnosis (57% localized vs 67% women) (82% 92%, respectively) every disease (eg, 20% 30%, respectively, distant stage). Breast surpassed as leading cause 2019. Targeted interventions needed reduce stark inequalities community.
Язык: Английский
Процитировано
458
JAMA Oncology, Год журнала: 2021, Номер 7(12), С. 1824 - 1824
Опубликована: Окт. 21, 2021
Updated estimates of non-small cell lung cancer (NSCLC) in the US are needed.To calculate most recent epidemiologic NSCLC US.This cross-sectional epidemiological analysis used recently released data from registries. The population-based Cancer Statistics (USCS) database (2010-2017), comprised Surveillance, Epidemiology, and End Results (SEER) program National Program Registries (NPCR) (collectively, SEER-NPCR) provided incidence estimate. SEER-18 for incidence, prevalence, survival, initial treatment by stage. Adults aged 18 years or older diagnosed with identified International Classification Diseases Oncology, Third Edition, morphology codes were included.Annual age-adjusted per 100 000 persons; annual prevalence survival rate; treatment. Due to release delays, available through 2017, other parameters 2016. was conducted June 2020 July 2020.There 1.28 million new cases recorded during 2010 2017 (SEER-NPCR: 53% male; 67% ≥ 65 years). From decreased 46.4 40.9 overall (age <65 years: 15.5 13.5; age ≥65 259.9 230.0); stage II, IIIA, IIIB stable, IV slightly 21.7 19.6, whereas I increased 10.8 13.2. 2016, 175.3 198.3 (nationwide projection SEER-18); among younger patients (77.5 87.9) but (825.1 812.4). Period found that 26.4% survived 5 years, which is higher than previously reported. proportion treated radiation as single rose markedly 14.7% 25.7% Patients likely be untreated (38.3%).The findings this suggest at diagnosis reflected improved evaluation incidental nodules. A smaller treated. Earlier detection availability effective treatments may underlie reported survival.
Язык: Английский
Процитировано
408
Cancer, Год журнала: 2022, Номер 128(24), С. 4251 - 4284
Опубликована: Окт. 27, 2022
Abstract Background The American Cancer Society, the Centers for Disease Control and Prevention, National Institute, North Association of Central Registries collaborate to provide annual updates on cancer occurrence trends in United States. Methods Data new diagnoses during 2001–2018 were obtained from Registries’ America Incidence file, which is comprised data Prevention‐funded Institute‐funded, population‐based registry programs. deaths 2001–2019 Center Health Statistics' Vital Statistics System. Five‐year average incidence death rates along with all cancers combined leading types are reported by sex, racial/ethnic group, age. Results Overall 497 per 100,000 among males (ranging 306 Asian/Pacific Islander 544 Black males) 431 females 309 473 Indian/Alaska Native females) 2014–2018. trend corresponding period was stable increased 0.2% year females, differing type. Among males, three (including pancreas kidney), seven prostate), decreased eight lung larynx) 18 most common considered this analysis. melanoma, liver, breast), four uterus), thyroid ovary) cancers. 2.3% 1.9% 2015–2019, sex‐specific declining reflected every major group. During 11 19 14 20 steepest declines (>4% year) melanoma. survival adenocarcinoma neuroendocrine pancreatic improved between 2001 2018; however, overall (2001–2018) mortality (2001–2019) continued increase site. children (younger than 15 years), recent mortality; among, adolescents young adults (aged 15–39 declined mortality. Conclusions decline overall, children, adults, treatment advances have led accelerated several sites, such as increases part reflect changes risk factors, screening test use, diagnostic practice. Racial/ethnic differences exist mortality, highlighting need understand address inequities. Population‐based inform prevention, early detection, efforts help reduce burden
Язык: Английский
Процитировано
355
Cancer, Год журнала: 2024, Номер 130(8), С. 1330 - 1348
Опубликована: Янв. 27, 2024
Abstract Despite decades of declining mortality rates, lung cancer remains the leading cause death in United States. This article examines incidence, stage at diagnosis, survival, and using population‐based data from National Cancer Institute, Centers for Disease Control Prevention, North American Association Central Registries. Over past 5 years, declines became considerably greater than incidence among men (5.0% vs. 2.6% annually) women (4.3% 1.1% annually), reflecting absolute gains 2‐year relative survival 1.4% annually. Improved outcomes likely reflect advances treatment, increased access to care through Patient Protection Affordable Care Act, earlier diagnosis; example, compared with a 4.6% annual decrease distant‐stage disease during 2013–2019, rate localized‐stage rose by 3.6% Localized more steeply states highest screening prevalence (by 3%–5% those lowest 1%–2% annually). progress, disparities remain. For Native Americans have slowest decline (less 1% annually stagnant rates women) any group. In addition, Mississippi Kentucky are two three times higher most western states, largely because elevated historic smoking that remains. Racial geographic inequalities highlight longstanding opportunities concerted tobacco‐control efforts targeted high‐risk populations, including improved smoking‐cessation treatments screening, as well state‐of‐the‐art treatment.
Язык: Английский
Процитировано
182
British Journal of Pharmacology, Год журнала: 2023, Номер 181(3), С. 362 - 374
Опубликована: Окт. 3, 2023
Abstract Background and Purpose Survival rate of patients with lung cancer has increased by over 60% in the recent two decades. With longer survival, identification genes associated survival emerged as an issue utmost importance to uncover most promising biomarkers therapeutic targets. Experimental Approach An integrated database was set up combining multiple independent datasets clinical data transcriptome‐level gene expression measurements. Univariate multivariate analyses were performed identify higher levels linked shorter survival. The strongest filtered include only those known druggability. Key Results entire includes 2852 tumour specimens from 17 cohorts. Of these, 2227 have overall 1256 samples progression‐free time. significant MIF , UBC B2M adenocarcinoma ANXA2 CSNK2A2 KRT18 squamous cell carcinoma. We also aimed reveal best druggable targets non‐smokers cancer. three hits this cohort MDK THY1 PADI2 . established added Kaplan–Meier plotter ( https://www.kmplot.com ) enabling validation future expression‐based both present yet unexamined subgroups patients. Conclusions Implications In study, we a comprehensive for can be utilized rank different subtypes
Язык: Английский
Процитировано
143
CA A Cancer Journal for Clinicians, Год журнала: 2025, Номер unknown
Опубликована: Янв. 16, 2025
ABSTRACT Each year, the American Cancer Society estimates numbers of new cancer cases and deaths in United States compiles most recent data on population‐based occurrence outcomes using incidence collected by central registries (through 2021) mortality National Center for Health Statistics 2022). In 2025, 2,041,910 618,120 are projected to occur States. The rate continued decline through 2022, averting nearly 4.5 million since 1991 because smoking reductions, earlier detection some cancers, improved treatment. Yet alarming disparities persist; Native people bear highest mortality, including rates that two three times those White kidney, liver, stomach, cervical cancers. Similarly, Black have two‐fold higher than prostate, uterine corpus Overall has generally declined men but risen women, narrowing male‐to‐female ratio (RR) from a peak 1.6 (95% confidence interval, 1.57–1.61) 1992 1.1 1.12–1.12) 2021. However, women aged 50–64 years already surpassed (832.5 vs. 830.6 per 100,000), younger (younger 50 years) an 82% their male counterparts (141.1 77.4 up 51% 2002. Notably, lung among 65 2021 (15.7 15.4 100,000; RR, 0.98, p = 0.03). summary, continues decline, future gains threatened rampant racial inequalities growing burden disease middle‐aged young adults, especially women. Continued progress will require investment prevention access equitable treatment, individuals.
Язык: Английский
Процитировано
90